Literature DB >> 9778442

The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics.

D J Austin1, N J White, R M Anderson.   

Abstract

The use of simple mathematical models to study the kinetics of drug action and decay within vertebrate hosts has a long history with a major objective being to derive drug dosage regimens that optimize efficacy and minimize toxicity to the patient. Mathematical models of the relationship between dosage, route of delivery, drug concentration in defined sites and effect on a particular pathogen are widely used in the pharmacological literature. A more recent literature is that concerned with the population dynamics of pathogen replication within the host subjected to pressures exerted by the human immune system. In this paper we develop a theoretical framework to meld both approaches with the aim of identifying threshold criteria that dictate the optimum pattern of drug administration for pathogen clearance from the host. In particular we show how the percentage reduction in microparasite abundance is related to the pharmacokinetic parameter, AUC, recording the area under the drug concentration-time curve within the treated patient, in terms of the parameters that define the population dynamics of the pathogen and the properties of the drug. Two particular pathogens are examined to illustrate the principles underpinning the dynamics of the pharmacokinetic-population dynamic models, namely HIV and Plasmodium falciparum. Criteria for pathogen persistence or elimination are derived for these specific models based on the definition of a basic reproductive number, R0, which measures the average number of secondary infected target cells in a host generated by a single infected cell (CD4 lymphocyte for HIV, and erythrocyte for P. falciparum) within a population of susceptible cells. For the pathogen to invade the host and persist over time, R0</=1. Under chemotherapeutic regimens, expressions for R0 are derived allowing estimates to be made of the ideal treatment regime required to eliminate the pathogen, both for HIV and P. falciparum malaria. Copyright 1998 Academic Press

Entities:  

Mesh:

Year:  1998        PMID: 9778442     DOI: 10.1006/jtbi.1997.0438

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  33 in total

1.  Adherence and drug resistance: predictions for therapy outcome.

Authors:  L M Wahl; M A Nowak
Journal:  Proc Biol Sci       Date:  2000-04-22       Impact factor: 5.349

Review 2.  The evolution of drug-resistant malaria: the role of drug elimination half-life.

Authors:  Ian M Hastings; William M Watkins; Nicholas J White
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

3.  Link between immune response and parasite synchronization in malaria.

Authors:  Igor M Rouzine; F Ellis McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-05       Impact factor: 11.205

4.  Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 5.  Regulating the use of antibiotics in the community.

Authors:  C Carbon; R P Bax
Journal:  BMJ       Date:  1998-09-05

6.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 7.  Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs.

Authors:  Julie A Simpson; Sophie Zaloumis; Alysha M DeLivera; Ric N Price; James M McCaw
Journal:  AAPS J       Date:  2014-07-24       Impact factor: 4.009

8.  Exploring the role of the immune response in preventing antibiotic resistance.

Authors:  Andreas Handel; Elisa Margolis; Bruce R Levin
Journal:  J Theor Biol       Date:  2008-11-08       Impact factor: 2.691

9.  The impact of different antibiotic regimens on the emergence of antimicrobial-resistant bacteria.

Authors:  Erika M C D'Agata; Myrielle Dupont-Rouzeyrol; Pierre Magal; Damien Olivier; Shigui Ruan
Journal:  PLoS One       Date:  2008-12-29       Impact factor: 3.240

10.  Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.

Authors:  Romulus Breban; Sonia Napravnik; James Kahn; Sally Blower
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.